WuXi STA, a Contract Research, Development, and Manufacturing Organization (CRDMO), broke ground for its new 190-acre pharmaceutical manufacturing campus in Middletown, DE. First announced in June 2021, this site will be WuXi STA’s second facility in the U.S., offering expanded capacity and greater flexibility to meet customer needs in the U.S. and around the world.
 
The WuXi STA Middletown site is located in the Middletown Business Center at 1091 Industrial Drive, and the new state-of-the-art facility will create approximately 500 full-time jobs by 2026. Phase I of the new campus will provide formulation development, clinical and commercial drug product manufacturing services for a variety of oral and injectable dosage forms, as well as packaging, labeling, storage and distribution services for clinical trial materials and commercial drug products.
 
WuXi STA has 12 sites across the U.S., Europe and Asia. Together with three other drug product manufacturing sites in Couvet (Switzerland), Wuxi City (China) and Shanghai (China), this new facility will further enhance the company’s global drug production capacity and capabilities.

“The biopharmaceutical industry is part of Delaware’s DNA,” said Delaware Governor John Carney. “Over the next five years, WuXi STA plans to build a state-of-the-art pharmaceutical manufacturing campus in one of Delaware’s fastest-growing communities, bringing with it good jobs and economic growth. This campus is only possible because of Delaware’s world-class, innovative workforce. Thank you to WuXi STA, Middletown Mayor Kenny Branner and everyone who made this project possible.”